Not all breast cancer patients benefit from neoadjuvant or adjuvant therapy, resulting in considerable undertreatment or overtreatment. New insights into the role of tumor-infiltrating immune cells suggest that their composition, as well as their functionality, might serve as a biomarker to enable optimal patient selection for current systemic therapies and upcoming treatment options such as immunotherapy.SCOPUS: re.jinfo:eu-repo/semantics/publishe
Background: Pre-treatment tumour-associated lymphocytes (TILs) and stromal lymphocytes (SLs) are ind...
Background. The role of tumor-infiltrating lymphocytes (TILs) in breastcancer (BC) is still an issue...
Recently, immune edition has been recognized as a new hallmark of cancer. In this respect, some clin...
Background: Not all breast cancer patients benefit from neoadjuvant or adjuvant therapy, resulting i...
Background: Not all breast cancer patients benefit from neoadjuvant or adjuvant therapy, resulting i...
Background: Not all breast cancer patients benefit from neoadjuvant or adjuvant therapy, resulting i...
Background: Not all breast cancer patients benefit from neoadjuvant or adjuvant therapy, resulting i...
Background: Not all breast cancer patients benefit from neoadjuvant or adjuvant therapy, resulting i...
Background: Not all breast cancer patients benefit from neoadjuvant or adjuvant therapy, resulting i...
While breast cancer has not been considered a cancer amenable to immunotherapeutic approaches, recen...
In recent years, results obtained from different studies with large cohorts have revealed a bond bet...
Introduction: The antitumor host immune response is an important factor in breast cancer, but its ro...
The prognostic value of the immune cell infiltrate in the breast carcinoma microenvironment is still...
The prognostic value of the immune cell infiltrate in the breast carcinoma microenvironment is still...
Background: Pre-treatment tumour-associated lymphocytes (TILs) and stromal lymphocytes (SLs) are ind...
Background: Pre-treatment tumour-associated lymphocytes (TILs) and stromal lymphocytes (SLs) are ind...
Background. The role of tumor-infiltrating lymphocytes (TILs) in breastcancer (BC) is still an issue...
Recently, immune edition has been recognized as a new hallmark of cancer. In this respect, some clin...
Background: Not all breast cancer patients benefit from neoadjuvant or adjuvant therapy, resulting i...
Background: Not all breast cancer patients benefit from neoadjuvant or adjuvant therapy, resulting i...
Background: Not all breast cancer patients benefit from neoadjuvant or adjuvant therapy, resulting i...
Background: Not all breast cancer patients benefit from neoadjuvant or adjuvant therapy, resulting i...
Background: Not all breast cancer patients benefit from neoadjuvant or adjuvant therapy, resulting i...
Background: Not all breast cancer patients benefit from neoadjuvant or adjuvant therapy, resulting i...
While breast cancer has not been considered a cancer amenable to immunotherapeutic approaches, recen...
In recent years, results obtained from different studies with large cohorts have revealed a bond bet...
Introduction: The antitumor host immune response is an important factor in breast cancer, but its ro...
The prognostic value of the immune cell infiltrate in the breast carcinoma microenvironment is still...
The prognostic value of the immune cell infiltrate in the breast carcinoma microenvironment is still...
Background: Pre-treatment tumour-associated lymphocytes (TILs) and stromal lymphocytes (SLs) are ind...
Background: Pre-treatment tumour-associated lymphocytes (TILs) and stromal lymphocytes (SLs) are ind...
Background. The role of tumor-infiltrating lymphocytes (TILs) in breastcancer (BC) is still an issue...
Recently, immune edition has been recognized as a new hallmark of cancer. In this respect, some clin...